The Medicines Company (NASDAQ: MDCO) announced today that the U.S. FDA has granted pediatric exclusivity for Angiomax (bivalirudin), based on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE